Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $445639.0.

  • 60 Degrees Pharmaceuticals' Change in Accured Expenses rose 82812.45% to $445639.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $785379.0, marking a year-over-year increase of 7608.84%. This contributed to the annual value of $501412.0 for FY2024, which is 33350.38% up from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $445639.0 for Q3 2025, which was up 82812.45% from -$252166.0 recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Change in Accured Expenses ranged from a high of $445639.0 in Q3 2025 and a low of -$788990.0 during Q3 2023
  • For the 4-year period, 60 Degrees Pharmaceuticals' Change in Accured Expenses averaged around $77811.2, with its median value being $100153.0 (2024).
  • As far as peak fluctuations go, 60 Degrees Pharmaceuticals' Change in Accured Expenses plummeted by 191841.02% in 2023, and later surged by 102681.24% in 2025.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Change in Accured Expenses stood at $226100.0 in 2022, then rose by 21.45% to $274603.0 in 2023, then increased by 20.17% to $330001.0 in 2024, then soared by 35.04% to $445639.0 in 2025.
  • Its last three reported values are $445639.0 in Q3 2025, -$252166.0 for Q2 2025, and $261905.0 during Q1 2025.